Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 28 September 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Coffee reduces risk for hepatocellular carcinoma

Coffee consumption reduces the risk for hepatocellular carcinoma, finds the most recent issue of the Clinical Gastroenterology & Hepatology.

News image

Coffee consumption has been suggested to reduce the risk for hepatocellular carcinoma (HCC).

Dr  Carlo La Vecchia and colleagues performed a meta-analysis of epidemiological studies to provide updated information on how coffee drinking affects HCC risk.

The researchers performed a PubMed/MEDLINE search of the original articles published in English from 1966 through 2012, on case-control or cohort studies that associated coffee consumption with liver cancer or HCC.

The researchers calculated the summary relative risk for any, low, and high consumption of coffee vs no consumption.

The cut-off point for low vs high consumption was set to 3 cups per day in 9 studies, and 1 cup per day in 5 studies.

The relative risk was 0.80 for an increment of 1 cup of coffee per day
Clinical Gastroenterology & Hepatology

The team noted that the summary relative risk for any coffee consumption vs no consumption was 0.60 from 16 studies, comprising a total of 3153 HCC cases.

The researchers found that the relative risks were 0.56 from 8 case-control studies, and 0.64 from 8 cohort studies.

Compared with no coffee consumption, the team found that the summary relative risk was 0.72 for low consumption, and 0.44 for high consumption.

The summary relative risk was 0.80 for an increment of 1 cup of coffee per day.

The team found that the inverse relationship between coffee, and HCC risk was consistent regardless of the subjects’ sex, alcohol drinking, or history of hepatitis or liver disease.

Dr La Vecchia's team commented, "From this meta-analysis, the risk of HCC is reduced by 40% for any coffee consumption vs no consumption."

"The inverse association might partly or largely exist because patients with liver and digestive diseases reduce their coffee intake."

"However, coffee has been shown to affect liver enzymes and development of cirrhosis, and therefore could protect against liver carcinogenesis."

Clin Gastroenterol Hepatol 2013: 11(11): 1413-1421.e1
25 October 2013

Go to top of page Email this page Email this page to a colleague

 28 September 2016 
Heterogeneity in endoscopic treatment of Crohn’s
 28 September 2016 
Global trends in pancreatic cancer mortality
 28 September 2016 
Hep C virus RNA in liver explants
 27 September 2016 
Non-invasive tests of NAFLD
 27 September 2016 
Fecal microbiota transplantation for C.diff in IBD
 27 September 2016 
Fast-track colorectal surgery influences outcomes
 26 September 2016 
Preventing cirrhosis in Hep C with fibrosis
 26 September 2016 
Body image after abdominoperineal excision for rectal cancer
 26 September 2016 
Gastric cancer risk in intestinal metaplasia of the stomach
 23 September 2016 
Sleep quality in nonalcoholic cirrhotic patients
 23 September 2016 
Exercise for NAFLD
 23 September 2016 
BMI history and fatty liver
 22 September 2016 
Predicting small-bowel Crohn’s disease
 22 September 2016 
Colectomy outcomes for ulcerative colitis
 22 September 2016 
Technology vs intervention for weight loss
 21 September 2016 
Employment status and IBD
 21 September 2016 
Cardiopulmonary exercise testing in liver transplant candidates
 21 September 2016 
Patients vs providers on nutrition in IBD
 20 September 2016 
Improving healthcare systems for viral Hepatitis
 20 September 2016 
GI benefits of COX-2 selective inhibitors
 20 September 2016 
Predicting relapse in Crohn's
 19 September 2016 
Prevalence of esophageal cancer in Barrett's
 19 September 2016 
Fecal microbiota transplantation and CDI in IBD
 19 September 2016 
Antibiotic resistance in Helicobacter pylori
 16 September 2016 
Low-residue diet before colonoscopy and bowel cleansing
 16 September 2016 
Genome-wide association in gastric cancer
 16 September 2016 
H. pylori in children with asthma
 15 September 2016 
Improving survival in cholangitis-associated septic shock
 15 September 2016 
Primary sclerosing cholangitis and IBD
 15 September 2016 
Colorectal cancer survival and hospital volumes
 14 September 2016 
Intestinal malabsorption and olmesartan
 14 September 2016 
Infection reduction strategy after colorectal resection
 14 September 2016 
Predicting long-term infliximab use in Crohn's
 13 September 2016 
Predicting survival in refractory celiac disease
 13 September 2016 
Cancer risk stratification in Barrett’s
 13 September 2016 
Screening vs non-screening colonoscopy
 12 September 2016 
Screening in familial colorectal cancer
 12 September 2016 
Metformin improves survival in pancreatic ductal cancer
 12 September 2016 
Consent guidelines for GI endoscopy procedures
 09 September 2016 
Development of IBS
 09 September 2016 
Safe and effective treatment for NASH
 09 September 2016 
Scale for stool measurement in diarrhea-IBS
 08 September 2016 
Prognostic factors for infliximab in Crohn's
 08 September 2016 
Chronic Hep B vs chronic Hep C and mortality
 08 September 2016 
Hematological malignancies in IBD
 07 September 2016 
IBD relapse during pregnancy
 07 September 2016 
New treatments for ulcerative colitis
 07 September 2016 
Alternative to nucleic acid testing in HCV
 06 September 2016 
Endoscopy clinic no-shows
 06 September 2016 
Risk of infection after elective colorectal surgery
 06 September 2016 
EHealth technologies in IBD
 05 September 2016 
Esophageal impedance monitoring
 05 September 2016 
Family history and IBD clinical course
 05 September 2016 
Biomarker for IBD and GI cancer
 02 September 2016 
Dietary carbohydrate intake, insulin resistance and GERD 
 02 September 2016 
Postpolypectomy bleeding in the colorectum
 02 September 2016 
Postop recurrence of Crohn's
 01 September 2016 
Prognostic test for liver transplants
 01 September 2016 
Recovery after colorectal surgery in elderly patients
 01 September 2016 
Obesity and post-ERCP pancreatitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us